Publication:
Congenital and Fetal Effects After Mifepristone Exposure and Continuation of Pregnancy: A Systematic Review

Simple item page
cris.virtual.department#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.department#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.department#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.departmentfa719479-ceec-4c0b-a128-208cce7b2f99
cris.virtualsource.departmented68f7b5-264b-47c6-b87e-8f7ecbfce61f
cris.virtualsource.departmentb090e6df-f049-4770-9377-7e084b5dd60b
cris.virtualsource.orcidfa719479-ceec-4c0b-a128-208cce7b2f99
cris.virtualsource.orcided68f7b5-264b-47c6-b87e-8f7ecbfce61f
cris.virtualsource.orcidb090e6df-f049-4770-9377-7e084b5dd60b
dc.contributor.authorTurner, Joseph Ven
dc.contributor.authorGarratt, Deborahen
dc.contributor.authorBarwick, Annaen
dc.contributor.authorMcLindon, Lucas Aen
dc.contributor.authorSpark, M Joyen
dc.contributor.authorSmith, Angelaen
dc.date.accessioned2024-10-19T07:16:32Z
dc.date.available2024-10-19T07:16:32Z
dc.date.presented2024
dc.description.abstract<p>Mifepristone is an anti-progestational drug that is the first component of the standard medical abortion regimen. For women who take mifepristone and then do not take misoprostol, which is the second component of the medical abortion regimen, it is possible that their pregnancy may continue to live birth. Since mifepristone is commonly used for medical abortion up to 9–10 weeks gestation, any adverse or teratogenic effects on the developing embryo/fetus must be considered, given exposure during the critical time of its development and organogenesis. Toxicology and teratology reports have cited studies demonstrating teratogenic effect of mifepristone in some animals. Current clinical guidelines for women exposed to mifepristone in the first trimester of pregnancy state that it is not known to be teratogenic based on limited published evidence from humans. The aim of this narrative systematic review was to investigate embryonic/fetal exposure to mifepristone and any association with congenital or fetal anomalies. This study was conducted by systematic searches of health databases from inception to February 2024. The references of relevant citations were manually searched to retrieve any additional citations not captured in database searching. Congenital anomalies and adverse outcomes were encountered at various doses of mifepristone exposure. A number of the congenital anomalies encountered in this review were explained by circumstances other than exposure to mifepristone. The present systematic review did not find data to support mifepristone being implicated as a teratogen.</p>en
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.academiclevelAcademicen
dc.identifier.citationClinical Pharmacology & Therapeutics, 116(5), p. 1207-1216en
dc.identifier.doi10.1002/cpt.3392en
dc.identifier.issn1532-6535en
dc.identifier.issn0009-9236en
dc.identifier.staffune-id:jturne59en
dc.identifier.staff#PLACEHOLDER_PARENT_METADATA_VALUE#en
dc.identifier.staffune-id:aunger2en
dc.identifier.staff#PLACEHOLDER_PARENT_METADATA_VALUE#en
dc.identifier.staffune-id:jsparken
dc.identifier.staff#PLACEHOLDER_PARENT_METADATA_VALUE#en
dc.identifier.urihttps://hdl.handle.net/1959.11/63560
dc.languageenen
dc.publisherJohn Wiley & Sons, Incen
dc.relation.ispartofClinical Pharmacology & Therapeuticsen
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleCongenital and Fetal Effects After Mifepristone Exposure and Continuation of Pregnancy: A Systematic Reviewen
dc.typeJournal Articleen
dcterms.accessRightsUNE Greenen
dspace.entity.typePublication
local.access.fulltextYesen
local.atsiresearchNoen
local.codeupdate.date2024-11-05T14:17:21.317en
local.codeupdate.epersonjspark@une.edu.auen
local.codeupdate.finalisedtrueen
local.contributor.firstnameJoseph Ven
local.contributor.firstnameDeborahen
local.contributor.firstnameAnnaen
local.contributor.firstnameLucas Aen
local.contributor.firstnameM Joyen
local.contributor.firstnameAngelaen
local.contributor.lastnameTurneren
local.contributor.lastnameGarratten
local.contributor.lastnameBarwicken
local.contributor.lastnameMcLindonen
local.contributor.lastnameSparken
local.contributor.lastnameSmithen
local.date.moved2024-10-25en
local.fileurl.openhttps://rune.une.edu.au/web/retrieve/f1c283fe-0033-48fd-a6fa-8e5ac5709790en
local.fileurl.openpublishedhttps://rune.une.edu.au/web/retrieve/f1c283fe-0033-48fd-a6fa-8e5ac5709790en
local.format.endpage1216en
local.format.startpage1207en
local.identifier.erajournal14721en
local.identifier.issue5en
local.identifier.unepublicationidune:1959.11/63560en
local.identifier.volume116en
local.open.fileurlhttps://rune.une.edu.au/web/retrieve/f1c283fe-0033-48fd-a6fa-8e5ac5709790en
local.original.for20203214 Pharmacology and pharmaceutical sciencesen
local.original.seo2020tbden
local.output.categoryC1en
local.output.categorydescriptionC1 Refereed Article in a Scholarly Journalen
local.peerreviewedYesen
local.profile.affiliationtypeUNE Affiliationen
local.profile.affiliationtypeUNE Affiliationen
local.profile.affiliationtypeUNE Affiliationen
local.profile.affiliationtypeExternal Affiliationen
local.profile.affiliationtypeUNE Affiliationen
local.profile.affiliationtypeExternal Affiliationen
local.profile.emailjturne59@une.edu.auen
local.profile.email#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.emailaunger2@une.edu.auen
local.profile.email#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.emailjspark@une.edu.auen
local.profile.email#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.orcid0000-0002-0023-4275en
local.profile.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.orcid0000-0003-4504-3453en
local.profile.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.orcid0000-0001-5240-8217en
local.profile.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.roleauthoren
local.profile.schoolSchool of Rural Medicineen
local.profile.school#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.schoolSchool of Rural Medicineen
local.profile.school#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.profile.schoolSchool of Rural Medicineen
local.profile.school#PLACEHOLDER_PARENT_METADATA_VALUE#en
local.publisher.placeUnited States of Americaen
local.record.institutionUniversity of New Englanden
local.record.placeauen
local.search.authorTurner, Joseph Ven
local.search.authorGarratt, Deborahen
local.search.authorBarwick, Annaen
local.search.authorMcLindon, Lucas Aen
local.search.authorSpark, M Joyen
local.search.authorSmith, Angelaen
local.sensitive.culturalNoen
local.sourceriskNoen
local.subject.for2020321402 Clinical pharmacology and therapeuticsen
local.subject.for2020321502 Obstetrics and gynaecologyen
local.subject.seo2020200105 Treatment of human diseases and conditionsen
local.subject.seo2020200509 Women''s and maternal healthen
local.title.maintitleCongenital and Fetal Effects After Mifepristone Exposure and Continuation of Pregnancyen
local.title.subtitleA Systematic Reviewen
local.uneassociationYesen
local.year.presented2024en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
openpublished/CongenitalTurnerBarwick2024JournalArticle.pdf
Size:
470.11 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
Collections
Journal Article
School of Rural Medicine